Mochida Pharmaceutical Co., Ltd.

TSE:4534.T

3280 (JPY) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 102,885103,261110,179102,995101,801109,652106,74997,35392,27487,26193,95389,23086,19679,32578,54875,16774,59374,07070,64068,025
Cost of Revenue 50,81548,14650,62648,20349,88255,47753,18241,04337,27333,91334,36432,79729,84130,37229,09928,48928,34129,08826,80227,314
Gross Profit 52,07055,11559,55354,79251,91954,17553,56756,31055,00153,34859,58956,43356,35548,95349,44946,67846,25244,98243,83840,711
Gross Profit Ratio 0.5060.5340.5410.5320.510.4940.5020.5780.5960.6110.6340.6320.6540.6170.630.6210.620.6070.6210.598
Reseach & Development Expenses 12,55413,28312,29510,84911,88413,00311,91215,22613,45411,77711,96112,51900000000
General & Administrative Expenses 46,26746,60728,61527,60026,78426,16925,31025,25524,80624,89025,61424,61300000000
Selling & Marketing Expenses -12,554-13,2834,2514,3394,4444,4124,6824,4554,5874,9915,4125,28200000000
SG&A 33,71333,32432,86631,93931,22830,58129,99229,71029,39329,88131,02629,89500000000
Other Expenses 10210811910410911941,9049141104111464035131,1767341,426-143322290
Operating Expenses 46,26746,60745,16142,78843,11243,58441,90444,93642,84541,65842,98742,41441,42637,44335,50033,69434,42734,58635,04035,943
Operating Income 5,8038,50714,39212,0038,80710,59011,66211,37412,15411,68916,60014,01714,92911,51013,94912,98411,82510,3968,7984,768
Operating Income Ratio 0.0560.0820.1310.1170.0870.0970.1090.1170.1320.1340.1770.1570.1730.1450.1780.1730.1590.140.1250.07
Total Other Income Expenses Net 357536199-105-2,5341,051454209-58-549-79543190-3,3551,8347432,328-11466-736
Income Before Tax 6,1609,04414,59111,9006,27311,64212,11611,58312,09711,14115,80614,06115,1198,15515,78313,72714,15310,2828,8644,032
Income Before Tax Ratio 0.060.0880.1320.1160.0620.1060.1130.1190.1310.1280.1680.1580.1750.1030.2010.1830.190.1390.1250.059
Income Tax Expense 1,6132,3954,0223,3121,6753,2073,0923,0573,9463,5975,9134,9096,0432,8215,9134,9735,8364,3763,9331,736
Net Income 4,5476,64910,5698,5874,5988,4359,0238,5268,1507,5449,8929,1529,0765,3339,8698,7548,3876,0304,9882,299
Net Income Ratio 0.0440.0640.0960.0830.0450.0770.0850.0880.0880.0860.1050.1030.1050.0670.1260.1160.1120.0810.0710.034
EPS 126.79178.93277.39222.27117.55212.86454.49214.73205.23188.64244.33221.13215.23121.1217.15188.18174.55122.2899.0344.18
EPS Diluted 126.79178.93277.39222.27117.55212.86454.49214.73205.23188.64244.33221.13215.23121.1217.15188.18174.55122.2899.0344.18
EBITDA 8,61111,59317,28615,10514,42113,84714,62914,39115,16914,93619,56817,08618,28914,92117,78416,26916,08513,39512,5298,957
EBITDA Ratio 0.0840.1120.1570.1470.1420.1260.1370.1480.1640.1710.2080.1910.2120.1880.2260.2160.2160.1810.1770.132